TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN CARDIAC AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN CARDIAC AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for heart transplant patients: drug may stop amyloidosis spread
Disease control Recruiting nowThis study tests whether the drug tafamidis can safely stop the progression of ATTR amyloidosis in other organs after a heart transplant. About 25 adults who had a heart transplant at least a year ago will take tafamidis for 12 months. Researchers will measure protein stability i…
Matched conditions: TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
AI-Powered ECG could spot hidden heart disease before symptoms appear
Diagnosis Recruiting nowThis study is testing a computer program called Willem that uses artificial intelligence to read electrocardiograms (ECGs) and detect a rare heart condition called transthyretin cardiac amyloidosis (ATTR-CA). Researchers will look at past ECGs from 2,000 adults—some with the dise…
Matched conditions: TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Sponsor: Idoven 1903 S.L. • Aim: Diagnosis
Last updated May 17, 2026 14:09 UTC